FDA reports prescribing, dispensing errors between Brintellix, Brilinta

The FDA recently released a warning to health care professionals and patients that reported confusion between the antidepressant Brintellix and the anti-blood clotting medication Brilinta is causing prescribing and dispensing errors.

The main reason for confusion is the similarity of brand names, according to the FDA.

There have been no reports that a patient ingested the incorrect medication, but reports of prescribing and dispensing errors have continued.

To reduce risk for confusion, the FDA recommends health care professionals include the generic name of the medication in addition to the brand name and the indication for use when prescribing these medications. The organization also recommends patients check their prescription to ensure the correct medication was dispensed.

For more information:

Visit http://www.fda.gov/Safety/MedWatch/SafetyInformation for more recommendations.